SNY - Sanofi

NYSE - NYSE Delayed Price. Currency in USD
39.95
-0.01 (-0.03%)
At close: 4:02PM EDT

39.95 -0.01 (-0.01%)
After hours: 4:02PM EDT

Stock chart is not supported by your current browser
Previous Close39.96
Open40.25
Bid0.00 x 0
Ask0.00 x 0
Day's Range39.95 - 40.27
52 Week Range38.14 - 50.65
Volume811,141
Avg. Volume1,762,385
Market Cap100.498B
Beta0.83
PE Ratio (TTM)9.76
EPS (TTM)4.09
Earnings DateN/A
Forward Dividend & Yield1.64 (4.04%)
Ex-Dividend Date2017-05-11
1y Target Est48.00
Trade prices are not sourced from all markets
  • Sanofi in talks to sell generics arm for $2.4 bln
    Reuters Videos7 days ago

    Sanofi in talks to sell generics arm for $2.4 bln

    French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion). Sonia Legg reports.

  • Motley Fool3 days ago

    Why Dicerna Rocketed Higher Today

    Investors are happy the biotech ended a lawsuit hanging over its head.

  • Reuters4 days ago

    WHO recommends testing before use of Sanofi's dengue vaccine

    The World Health Organisation on Thursday said Sanofi's vaccine against dengue should only be used after testing individuals to assess whether they could have been exposed before to the infection. "We have now clear information that the vaccine needs to be dealt in a safer way by using it exclusively in people already infected," Alejandro Cravioto, Chair of the WHO's Strategic Advisory Group of Experts (SAGE) on Immunization, told journalists. After new analysis of data, Sanofi warned in November the vaccine could increase the risk of severe dengue in some cases in people who had not been previously exposed to the disease.

  • Sanofi to Divest European Generic Unit, Streamline Business
    Zacks4 days ago

    Sanofi to Divest European Generic Unit, Streamline Business

    Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.

  • Analysts’ Recommendations for Novartis on April 17
    Market Realist5 days ago

    Analysts’ Recommendations for Novartis on April 17

    Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16. For 1Q18, analysts expect Novartis to see EPS of $1.28 on revenue of $12.6 billion.

  • Novartis’s 1Q18 Estimates: Expectations for Sandoz
    Market Realist6 days ago

    Novartis’s 1Q18 Estimates: Expectations for Sandoz

    Sandoz, the generics arm of Novartis (NVS), includes pharmaceuticals and biotechnological active substances in its portfolio. Sandoz is expected to report growth in operating revenue in 1Q18.

  • Reuters6 days ago

    Sanofi's CFO Contamine to retire later this year

    PARIS (Reuters) - Sanofi's (SASY.PA) executive vice president and chief financial officer, Jerome Contamine, plans to retire later this year, the French drugmaker said on Tuesday. In an emailed statement, ...

  • Sanofi Finance Chief to Leave After Almost a Decade at Drugmaker
    Bloomberg6 days ago

    Sanofi Finance Chief to Leave After Almost a Decade at Drugmaker

    Sanofi Chief Financial Officer Jerome Contamine is planning to step down from the French drugmaker later this year after almost a decade in the job.

  • Novartis’s Innovative Medicines Segment in 1Q18
    Market Realist6 days ago

    Novartis’s Innovative Medicines Segment in 1Q18

    Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products.

  • The Wall Street Journal7 days ago

    [$$] Advent in Exclusivity to Buy Czech Drugmaker Zentiva for €1.9 Billion

    The firm has presented a €1.9 billion ($2.35 billion) binding offer for the drugmaker.

  • In Pharma, If You Can't Join Them, Beat Them
    Bloomberg7 days ago

    In Pharma, If You Can't Join Them, Beat Them

    Advent is preparing to take on a drugmaker it tried and failed to buy.

  • Reuters7 days ago

    Bank trio expected to lead financing on Zentiva sale

    Goldman Sachs, JP Morgan and Morgan Stanley are expected to lead a debt financing totalling in excess of €1bn backing private equity firm Advent International’s acquisition of French healthcare group Sanofi’s (SASY.PA) European generics drugs arm Zentiva, banking sources said. Sanofi entered exclusive talks to sell Zentiva to Advent for €1.9bn, including equity and debt, the companies said on Tuesday.

  • Reuters7 days ago

    Sanofi in talks to sell generics arm to Advent for $2.4 billion

    French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion), the companies said on Tuesday. Sanofi said the sale was expected to be completed before the end of the year, and Advent's offer was binding and fully financed. The 1.9 billion euros price is an enterprise value, including equity and debt.

  • Reuters7 days ago

    Sanofi in talks to sell generics arm to Advent for $2.4 bln

    French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion), the companies said on Tuesday. Sanofi said the sale was expected to be completed before the end of the year, and Advent's offer was binding and fully financed. The 1.9 billion euros price is an enterprise value, including equity and debt.

  • Financial Times7 days ago

    [$$] Advent in exclusive talks to buy Sanofi generics business

    Private equity firm Advent has confirmed that it has entered into exclusive negotiations to buy Zentiva, Sanofi’s European generics business, for €1.91bn. A statement from the two firms on Tuesday said ...

  • The Wall Street Journal7 days ago

    [$$] Sanofi in Talks With Advent to Sell Zentiva

    Sanofi said it has entered exclusive talks to sell its European generic business Zentiva to Advent International for €1.92 billion.

  • Sanofi to Sell Generics for $2.4 Billion to Focus on Biotech
    Bloomberg7 days ago

    Sanofi to Sell Generics for $2.4 Billion to Focus on Biotech

    Sanofi plans to sell its European generic-drug unit to buyout firm Advent International Corp. for 1.9 billion euros ($2.4 billion) as part of a broader move by Chief Executive Officer Olivier Brandicourt ...

  • GlobeNewswire7 days ago

    Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business

      Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi`s European generics business Advent to invest in Zentiva to ...

  • Upadacitinib Could Drive AbbVie’s Long-Term Growth
    Market Realist7 days ago

    Upadacitinib Could Drive AbbVie’s Long-Term Growth

    In April 2018, AbbVie (ABBV) positive results for its Phase 3 SELECT-COMPARE trial, which evaluated the safety and efficacy of upadacitinib for adults with moderate-to-severe rheumatoid arthritis. The trial met its primary endpoint of improved ACR201 scores and clinical remission.

  • The Wall Street Journal7 days ago

    [$$] Charterhouse Portfolio Company Closes Sanofi Deal

    Cooper-Vemedia paid €158 million ($194.8 million) for 12 pharmaceutical brands.

  • Reuters8 days ago

    France's Sanofi sells 12 brands to Charterhouse's Cooper-Vemedia

    French healthcare and drugs group Sanofi (SASY.PA) has agreed to sell a portfolio of 12 pharmaceutical brands to Charterhouse Capital Partners' Cooper-Vemedia drugs manufacturing arm for 158 million euros (£136.6 million), the companies said on Monday. Sanofi said the sale formed part of its strategy to focus on its main businesses in areas such as allergy treatments and nutritional products, and to simplify its business portfolio. Private equity and investment firm Charterhouse Capital said the acquisition would help build up the healthcare portfolio of Cooper-Vemedia, which is a European drug manufacturer and distributor.

  • Advent Is Said to Near Deal to Acquire Sanofi Generics Unit
    Bloomberg8 days ago

    Advent Is Said to Near Deal to Acquire Sanofi Generics Unit

    Advent International Corp. is close to acquiring Sanofi’s European generics division in a deal valued at about 2 billion euros ($2.5 billion) including debt, people with knowledge of the matter said.

  • Financial Times9 days ago

    [$$] Advent nears deal to buy Sanofi generics business

    Advent International, the US buyout group, is close to clinching a deal to buy the European generics business of Sanofi , according to two people familiar with the transaction. The news comes after the ...

  • Financial Times11 days ago

    [$$] Advent leads race to buy Sanofi’s generics arm

    Advent International has pulled ahead in the race to acquire the European generics unit of French pharmaceutical company Sanofi as it tries to fend off competition from both trade and financial buyers, ...

  • Financial Times11 days ago

    [$$] Advent International closes in on deal for Sanofi’s generics unit

    Advent International has pulled ahead in the race to acquire the European generics unit of French pharmaceutical company Sanofi , as it tries to fend off competition from both trade and financial buyers, ...